INTRODUCTION AND OBJECTIVES: Prior experimental studies have shown that the enzyme g-glutamyltransferase (g-GT) is overexpressed during carcinogenetic transformation of urothelial cells. This analysis aimed to elucidate the prognostic value of serum g-GT, glutamat-pyruvat-transaminase (GPT) and glutamat-oxalattransaminase (GOT) levels in patients with invasive bladder cancer (BC).
METHODS: Preoperative serum g-GT, GPT and GOT concentrations were assessed in 324 patients treated with RC for clinically non-metastatic BC between 2002 and 2013. Laboratory values were obtained 1-3 days prior to RC. Uni-and multivariable analyses were carried out to evaluate clinicopathologic features and survival after RC. The median follow-up was 36 months (IQR: 10-55).
RESULTS: Elevated preoperative g-GT, GPT and GOT levels were diagnosed in 77 (23.8%), 20 (6.2%) and 18 (5.5%) patients, respectively. Elevated g-GT levels were significantly associated with advanced tumor stage (pT3a; p¼0.001), lymph-node tumor involvement (p<0.001), positive surgical margins (p¼0.018), lymphovascular invasion (p¼0.024), muscle-invasive disease at primary diagnosis (p¼0.033), increased tumor size (continuously coded; p¼0.035), receipt of neoadjuvant chemotherapy (p¼0.006), higher Eastern Cooperative Performance Status (p¼0.001), hydronephrosis at RC (p¼0.049), increased preoperative serum C-reactive protein levels (p<0.001) and elevated serum GPT and GOT levels (both p<0.001). Patients with elevated g-GT concentration exhibited inferior 3-year disease-free (52.5% vs. 63.2%; p¼0.19), cancer-specific (71.1% vs. 80.9%; p¼0.042) and overall survival rates (49.2% vs. 69.6%; p¼0.005) compared to patients with normal levels. On multivariable analysis, higher ECOG performance status, hydronephrosis at RC (both p¼0.010), positive surgical margin status (p¼0.014), lymph node positive disease (p¼0.030), advanced tumor stage (p¼0.032), and an elevated g-GT concentration (p¼0.043) were independent predictors of all-cause mortality.
CONCLUSIONS: Elevated preoperative g-GT levels are associated with a significantly increased risk for locally advanced bladder cancer and mortality. These data suggest that g-GT levels may be a useful prognostic marker for patients after RC for BC.
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MP88-02 EXPRESSION OF CLASS III BETA-TUBULIN PREDICTS PROGNOSIS IN CISPLATIN-RESISTANT BLADDER CANCER PATIENTS RECEIVING PACLITAXEL-BASED SECOND-LINE CHEMOTHERAPY
Tomohiro Matsuo*, Yasuyoshi Miyata, Yuichiro Nakamura, Takuji Yasuda, Kojiro Ohba, Hideki Sakai, Nagasaki, Japan INTRODUCTION AND OBJECTIVES: Class III beta-tubulin (TUBB3) is associated with malignant aggressiveness and prognosis, in addition, its expression is recognized as a predictive marker for taxanebased chemotherapy (CTx) in several cancers. In urothelial cancer (UC), standard first-line therapy for advanced disease is cisplatin (CDDP)-based CTx. On the other hand, although second-line regimen for CDDP-resistant tumor is not still established, several studies showed paclitaxel (PTX)-based regimens were effective to improve the prognosis. The main aim is to clarify the predictive value of TUBB3 expression for anti-cancer effect by first-line CDDP-based CTx and second-line PTX-based one in patients with UC.
METHODS: We reviewed 116 UC (bladder cancer ¼ 90 and upper urinary tract cancer ¼ 26) patients treated with CDDP-based regimen as first-line CTx. Among these patients, 53 patients were received PTX-based second-line CTx. As PTX-based CTx, the combination of gemcitabine and PTX were performed in 42 patients. TUBB3 expression was evaluated by immunohistochemical technique, and survival analyses were performed by using Kaplan-Meier survival curves and multivariate COX proportional hazard analysis.
RESULTS: Positively stained ratio of TUBB3 in grade 3 tumors (50 / 74 ¼ 67.6%) was significantly higher (P < 0.001) than that in grade 1 (0 / 5 ¼ 0.0%) and grade 2 (14 / 37 ¼ 37.8%). A similar trend was found in T stage; however, it did not reach the significant level (P ¼ 0.062). No significant relationship was found in age, sex, and metastasis. When the predictive value of TUBB3 expression for CDDP-based first-line CTx was investigated, it is not recognized as a significant predictive factor for progression-free survival (P ¼ 0.796). On the other hand, high expression of TUBB3 is significantly e1174 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 associated with unfavorable overall survival from starting of secondline CTx (P ¼ 0.013). Multivariate analysis model including all pathological features, part of a tumor, and regimen of second-line therapy showed that TUBB3 expression was identified as an independent predictor (hazard ratio ¼ 5.18, 95% confidential intervals ¼ 1.85 -14.53, P ¼ 0.002). CONCLUSIONS: The TUBB3 expression is associated with malignant potential in UC. TUBB3 expression was identified as a useful predictive factor for anti-cancer effects of second-line PTX-based CTx in advanced UC patients with CDDP-resistant tumors. Out information is useful to discuss treatment strategies for patients with CDDP-resistant UC.
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MP88-03 SEQUENCING OF A CANCER CELL SUBPOPULATION IDENTIFIES MICROMETASTASES IN BLADDER CANCER
Kris Prado*, Los Angeles, CA; Kelvin Zhang, Boston, MA; Matteo Pellegrini, Arnold Chin, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Latent recurrences despite favorable pathology has been a longstanding conundrum in surgical oncology. In muscle-invasive urothelial carcinoma of the bladder, patients with clinically localized disease (pT2 N0) have a recurrence rate of 11-35% following radical cystectomy, with recurrence rates in higher stages of localized disease up to 50-69% (pT4 N0). Recurrence with N0 disease may be attributed to lymph node micrometastases, therefore improved pathologic staging of lymph nodes may add precision to selecting adjuvant therapy as well as stratifying patients with metastatic disease. Here, we describe a diagnostic approach combining fluorescence activated cell sorting and next-generation sequencing that identifies micrometastases in a patient with muscle-invasive urothelial carcinoma of the bladder.
METHODS: Tumor specimens from multiple regions of patient's bladder tumor as well as lymph nodes were obtained and were dissociated into a single cell suspension. Fluorescence activated cell sorting using the surface markers CD44 and CD49f was utilized to isolate a cancer cell subpopulation associated with stemness. Wholeexome sequencing and RNA sequencing of total cells and the CD44+CD49f+ subpopulation in multiple tumor specimens and regional lymph nodes were performed in order to identify micrometastases and evaluate gene expression among the different regions and populations.
RESULTS: Pathology of the lymph nodes resected demonstrated N0 disease. Mean allele frequency analysis demonstrated a significant correlation between tumor cancer cells and cancer cells isolated from the lymph nodes. RNA-sequencing revealed intratumoral heterogeneity as well as enrichment for immune system and lipid metabolism gene sets in the micrometastatic cancer cell subpopulations.
CONCLUSIONS: Although pathology demonstrated no lymph node disease, we were able to isolate a cancer cell subpopulation from the pathologically negative lymph nodes. Whole-exome sequencing verified the cells isolated from the lymph nodes were indeed similar to the primary tumor and RNA-seq demonstrated differences in gene expression among the total population and subpopulation. Our analysis illustrates how next-generation sequencing of cancer cell subpopulations can be utilized to improve pathologic staging, and provide insight into cancer stem cell biology.
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MP88-04 THE ADAPTOR PROTEIN CRK-INDUCED ERBB2 EXPRESSION PROMOTES TUMOR PROGRESSION AND METASTASIS OF BLADDER CANCER VIA EXOSOMES
Kazuhiko Yoshida*, Tokyo, Japan; Masumi Tsuda, Ryuji Matsumoto, Shingo Semba, Taichi Kimura, Mishie Tanino, Hiroshi Nishihara, Sapporo, Japan; Tsunenori Kondo, Kazunari Tanabe, Tokyo, Japan; Shinya Tanaka, Sapporo, Japan INTRODUCTION AND OBJECTIVES: Molecular targeted therapies have been developed for various cancers, however; which have not advanced beyond conventional chemotherapy for the locally advanced and metastatic bladder cancer (BC). Therefore, establishment of more efficient therapeutic strategy is urgently desired. Recently, extracellular exosomes are paid attention as important mediators of intercellular communication. Tumor-derived exosomes have known to transfer proteins and nucleic acids from the cells of origin to target cells and affect tumor progression and metastatic process. We have been reported that signaling adaptor protein CRK promotes cell growth, invasion, and adhesion in various cancers, however; the relationship between CRK and exosomes has remained unknown. Here, we investigated the effects of CRK-mediated exosomes on tumor progression and metastasis of BC.
METHODS: Human BC cell line UM-UC-3 were stably transfected with pCSII-CMV-tdTomato-Luc, and CRK was knocked-down by shRNA technique. The parental and CRK-depleted cells (CRKi) were orthotopically injected into nude mice, and the tumor progression and metastasis were investigated using IVIS Spectrum. In in vitro setting, expression levels of proteins associated with cell growth, survival, and invasion were examined in parental and CRKi UM-UC-3 cells and their exosomes, and the proteins contained in exosomes were identified by LC-TOF/MS. Low grade BC 5637 cells and HUVECs were treated with exosomes from parental UM-UC-3 cells, and the cell proliferation and invasion were analyzed. Furthermore, the metastases in mice pretreated with exosomes from parental and CRKi cells were investigated.
RESULTS: CRKi UM-UC-3 cells inhibited the tumor progression and metastasis in orthotopic xenograft models. We found that CRK and ErbB2 were contained in exosome from the parental UM-UC-3 cells, and the exosomes-incorporated-5637 and -HUVECs significantly promote the cell proliferation and invasion. In contrast, in exosomes from CRKi cells, the expression levels of ErbB2 were reduced, and the exosome-incorporated recipient cells decreased the growth and invasion. Of note, lung metastasis of UM-UC-3 cells was facilitated in mice educated by the parental UM-UC-3-derived exosomes, but not by CRKi cells-derived exosomes.
CONCLUSIONS: Here, we provide novel findings that CRKregulated up-regulation of ErbB2 in the exosomes of BC facilitated the tumor progression and metastasis. Therefore, CRK and ErbB2 might be potent therapeutic targets to prevent the locally advanced and metastasis for BC patients. INTRODUCTION AND OBJECTIVES: Genome wide profiling studies across cancers have been key to the increased understanding of tumour heterogeneity and recent efforts from large muscle invasive bladder cancer (MIBC) cohorts have led to their classification into molecular subtypes displaying distinct genomic and transcriptomic features. Herein, we performed a comprehensive in silico immune transcriptomic profiling using publicly available datasets to identify Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e1175
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